140
Participants
Start Date
November 26, 2012
Primary Completion Date
March 29, 2016
Study Completion Date
March 29, 2016
LDK378
Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Novartis Investigative Site, Maastricht
Novartis Investigative Site, Marseille
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Milan
Maryland Oncology Hematology, P.A. SC, Rockville
Novartis Investigative Site, Monza
Novartis Investigative Site, Madrid
Levine Cancer Institute SC 1, Charlotte
Emory University School of Medicine/Winship Cancer Institute Dept of Oncology, Atlanta
Sarah Cannon Research Institute Drug Ship - 4, Nashville
Novartis Investigative Site, Seville
Novartis Investigative Site, Parma
Novartis Investigative Site, Cologne
University of Wisconsin Univ Wisc 2, Madison
Novartis Investigative Site, Livorno
University of Chicago Medical Center SC, Chicago
University of Kansas Cancer Center DeptofUofKansas CancerCenter-2, Kansas City
Novartis Investigative Site, Heidelberg
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville
U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas
Novartis Investigative Site, Paris
University of Colorado Hospital SC, Aurora
Novartis Investigative Site, Avellino
University of California at Los Angeles Reg-5, Los Angeles
University of California at San Diego, Moores Cancer Ctr SC, San Diego
Stanford University Medical Center Stanford Cancer Center(2), Stanford
Seattle Cancer Care Alliance SC-1, Seattle
Novartis Investigative Site, Singapore
City of Hope National Medical Center Dept of Oncology 2, Duarte
Cancer Center of Kansas Dept of CCK, Wichita
Massachusetts General Hospital Mass General, Boston
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Oshawa
Novartis Investigative Site, Toronto
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Perugia
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Kashiwa
Novartis Investigative Site, Akashi
Novartis Investigative Site, Okayama
Novartis Investigative Site, Sayama
Novartis Investigative Site, Sunto-gun
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Koto
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Groningen
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY